Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/61017
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChen, Yu-Mei-
dc.contributor.authorChen, Dong-Mei-
dc.contributor.authorWu, Qing-Mei-
dc.contributor.authorYe, Wen-Jun-
dc.contributor.authorZhao, Chun-Shen-
dc.contributor.authorZhou, Zhi-Xu-
dc.date.accessioned2022-12-15T05:56:27Z-
dc.date.available2022-12-15T05:56:27Z-
dc.date.issued2022-12-
dc.identifier.issn2583-1321 (Online); 0019-5103 (Print)-
dc.identifier.urihttp://nopr.niscpr.res.in/handle/123456789/61017-
dc.description1272-1277en_US
dc.description.abstractA series of N-(8-(3-ureidophenyl)imidazo[1,2-a]pyridin-6-yl)acetamide derivatives have been synthesized and evaluated for antitumor activity against SMMC7721 cells and HCT116 cells in vitro in order to initially screen out their biological properties and to reveal the role of 8-substituted urea phenyl imidazo[1,2-a]pyridine fragment in the ability of compounds to antitumor activity. The antitumor activity test has shown that most compounds exhibit excellent anticancer activity against SMMC7721 cells and HCT116 cells. The experimental results have proved that N-(8-(3- ureidophenyl)imidazo[1,2-a]pyridin-6-yl)acetamide derivatives containing imidazo[1,2-a]pyridine and urea are promising for further in-depth study of antitumor properties.en_US
dc.language.isoenen_US
dc.publisherNIScPR-CSIR,Indiaen_US
dc.sourceIJC Vol.61(12) [Dec 2022]en_US
dc.subjectImidazo[1,2-a]pyridineen_US
dc.subjectUreaen_US
dc.subjectAntitumor activityen_US
dc.titleSynthesis and antitumor activity of novel N-(8-(3-ureidophenyl)imidazo [1,2-a]pyridin-6-yl)acetamide derivativesen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.56042/ijc.v61i12.69444en_US
Appears in Collections:IJC Vol.61(12) [Dec 2022]

Files in This Item:
File Description SizeFormat 
IJC 61(12) 1272-1277.pdf3.4 MBAdobe PDFView/Open
IJC 61(12) 1272-1277_Supp.pdf1.77 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.